Summary:
- This article discusses the development of a new COVID-19 vaccine candidate called EXS-21546, which is being developed by the Israeli company Enlivex Therapeutics.
- The vaccine is designed to stimulate the immune system to fight the SARS-CoV-2 virus, the virus that causes COVID-19, by targeting specific immune cells called monocytes and macrophages.
- Early clinical trials have shown promising results, with the vaccine demonstrating a good safety profile and the ability to generate an immune response in participants. Further clinical trials are planned to evaluate the vaccine's effectiveness in preventing COVID-19 infection.